vs
Side-by-side financial comparison of Hologic (HOLX) and Sinclair, Inc. (SBGI). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $807.0M, roughly 1.3× Sinclair, Inc.). Hologic runs the higher net margin — 17.1% vs 2.5%, a 14.6% gap on every dollar of revenue. On growth, Sinclair, Inc. posted the faster year-over-year revenue change (4.0% vs 2.5%). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -1.3%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Sinclair, Inc., doing business as Sinclair Broadcast Group, is a publicly traded American telecommunications conglomerate that is controlled by the descendants of company founder Julian Sinclair Smith. Headquartered in the Baltimore suburb of Cockeysville, Maryland, the company is the second-largest television station operator in the United States by number of stations after Nexstar Media Group, owning or operating 193 stations across the country in over 100 markets, covering 40% of American ...
HOLX vs SBGI — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $807.0M |
| Net Profit | $179.1M | $20.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 0.0% |
| Net Margin | 17.1% | 2.5% |
| Revenue YoY | 2.5% | 4.0% |
| Net Profit YoY | -10.9% | — |
| EPS (diluted) | $0.79 | $0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $807.0M | ||
| Q4 25 | $1.0B | $836.0M | ||
| Q3 25 | $1.0B | $773.0M | ||
| Q2 25 | $1.0B | $784.0M | ||
| Q1 25 | $1.0B | $776.0M | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | $988.0M | $917.0M | ||
| Q2 24 | $1.0B | $829.0M |
| Q1 26 | — | $20.0M | ||
| Q4 25 | $179.1M | $109.0M | ||
| Q3 25 | $187.2M | $-1.0M | ||
| Q2 25 | $194.9M | $-64.0M | ||
| Q1 25 | $-17.4M | $-156.0M | ||
| Q4 24 | $201.0M | $176.0M | ||
| Q3 24 | $178.6M | $94.0M | ||
| Q2 24 | $194.5M | $17.0M |
| Q1 26 | — | — | ||
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — |
| Q1 26 | — | 0.0% | ||
| Q4 25 | 22.6% | 9.6% | ||
| Q3 25 | 22.6% | 7.5% | ||
| Q2 25 | 24.9% | 2.7% | ||
| Q1 25 | -0.7% | 1.8% | ||
| Q4 24 | 22.5% | 26.5% | ||
| Q3 24 | 23.3% | 19.5% | ||
| Q2 24 | 24.1% | 7.7% |
| Q1 26 | — | 2.5% | ||
| Q4 25 | 17.1% | 13.0% | ||
| Q3 25 | 17.8% | -0.1% | ||
| Q2 25 | 19.0% | -8.2% | ||
| Q1 25 | -1.7% | -20.1% | ||
| Q4 24 | 19.7% | 17.5% | ||
| Q3 24 | 18.1% | 10.3% | ||
| Q2 24 | 19.2% | 2.1% |
| Q1 26 | — | $0.28 | ||
| Q4 25 | $0.79 | $1.62 | ||
| Q3 25 | $0.84 | $-0.02 | ||
| Q2 25 | $0.86 | $-0.91 | ||
| Q1 25 | $-0.08 | $-2.30 | ||
| Q4 24 | $0.87 | $2.64 | ||
| Q3 24 | $0.75 | $1.43 | ||
| Q2 24 | $0.82 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | — |
| Total Assets | $9.2B | — |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $866.0M | ||
| Q3 25 | $2.2B | $526.0M | ||
| Q2 25 | $1.9B | $616.0M | ||
| Q1 25 | $1.6B | $631.0M | ||
| Q4 24 | $2.0B | $697.0M | ||
| Q3 24 | $2.3B | $536.0M | ||
| Q2 24 | $2.4B | $378.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $4.4B | ||
| Q3 25 | $2.5B | $4.1B | ||
| Q2 25 | $2.5B | $4.1B | ||
| Q1 25 | $2.5B | $4.2B | ||
| Q4 24 | $2.5B | $4.1B | ||
| Q3 24 | $2.5B | $4.1B | ||
| Q2 24 | $2.5B | $4.1B |
| Q1 26 | — | — | ||
| Q4 25 | $5.2B | $443.0M | ||
| Q3 25 | $5.0B | $347.0M | ||
| Q2 25 | $4.8B | $361.0M | ||
| Q1 25 | $4.6B | $436.0M | ||
| Q4 24 | $4.8B | $583.0M | ||
| Q3 24 | $5.1B | $415.0M | ||
| Q2 24 | $5.0B | $340.0M |
| Q1 26 | — | — | ||
| Q4 25 | $9.2B | $5.9B | ||
| Q3 25 | $9.0B | $5.6B | ||
| Q2 25 | $8.8B | $5.7B | ||
| Q1 25 | $8.5B | $5.8B | ||
| Q4 24 | $8.7B | $5.9B | ||
| Q3 24 | $9.2B | $5.8B | ||
| Q2 24 | $8.9B | $5.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | 9.84× | ||
| Q3 25 | 0.50× | 11.75× | ||
| Q2 25 | 0.52× | 11.30× | ||
| Q1 25 | 0.55× | 9.56× | ||
| Q4 24 | 0.53× | 7.02× | ||
| Q3 24 | 0.49× | 9.86× | ||
| Q2 24 | 0.51× | 12.08× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | 1.7% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $98.0M | ||
| Q3 25 | $355.1M | $-36.0M | ||
| Q2 25 | $343.3M | $122.0M | ||
| Q1 25 | $169.4M | $5.0M | ||
| Q4 24 | $189.3M | $198.0M | ||
| Q3 24 | $367.0M | $210.0M | ||
| Q2 24 | $405.8M | $-306.0M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $79.0M | ||
| Q3 25 | $341.4M | $-58.0M | ||
| Q2 25 | $330.5M | $105.0M | ||
| Q1 25 | $153.9M | $-11.0M | ||
| Q4 24 | $172.5M | $175.0M | ||
| Q3 24 | $350.6M | $193.0M | ||
| Q2 24 | $385.3M | $-329.0M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 9.4% | ||
| Q3 25 | 32.5% | -7.5% | ||
| Q2 25 | 32.3% | 13.4% | ||
| Q1 25 | 15.3% | -1.4% | ||
| Q4 24 | 16.9% | 17.4% | ||
| Q3 24 | 35.5% | 21.0% | ||
| Q2 24 | 38.1% | -39.7% |
| Q1 26 | — | 1.7% | ||
| Q4 25 | 1.4% | 2.3% | ||
| Q3 25 | 1.3% | 2.8% | ||
| Q2 25 | 1.3% | 2.2% | ||
| Q1 25 | 1.5% | 2.1% | ||
| Q4 24 | 1.6% | 2.3% | ||
| Q3 24 | 1.7% | 1.9% | ||
| Q2 24 | 2.0% | 2.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 0.90× | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | 1.13× | ||
| Q3 24 | 2.05× | 2.23× | ||
| Q2 24 | 2.09× | -18.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SBGI
| Media revenue | $701.0M | 87% |
| Other | $82.0M | 10% |
| Political advertising revenue | $18.0M | 2% |
| Non-media revenue | $6.0M | 1% |
